CD8A and neoplasm: Analysis of cells at 14 days after GL261 tumor implantation revealed that ZIKV treatment promoted increased numbers of CD45+ leukocytes (~6.5-fold), including CD4+ T cells (~7.8-fold), CD8+ T cells (~20.1-fold), CD3–NK1.1+ natural killer (NK) cells (~8-fold), CD3+NK1.1+ NKT cells (~4.8-fold), and CD8+CD44+CD69+CD103+ resident memory T cells (Trm) (~14.6-fold) compared with PBS-treated, tumor-bearing mice (Figure 2A).